Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05334329
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:27:11.853462+00:00
Published At
2025-10-15T00:00:00+00:00
Record Updated At
2025-10-15
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Advanced Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-10-15"
protocolSection.identificationModule.nctId
"NCT05334329"
protocolSection.identificationModule.officialTitle
"Phase 1 Trial of Umbilical Cord Blood Natural Killer Cells (CB-NK) Expressing Soluble IL-15 (sIL-15) and PD-L1 +/- Atezolizumab in Non-Small Cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Advanced Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Metastatic Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Refractory Lung Non-Small Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage III Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IIIC Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IV Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVA Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)
  • Stage IVB Lung Cancer AJCC v8 (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.